Abstract:Objective-The peroxisome proliferator-activated receptor (PPAR) delta regulates systemic lipid homeostasis and inflammation. However, the ability of PPAR delta agonists to improve the pathology of pre-established lesions and whether PPAR delta activation is atheroprotective in the setting of insulin resistance have not been reported. Here, we examine whether intervention with a selective PPAR delta agonist corrects metabolic dysregulation and attenuates aortic inflammation and atherosclerosis.Approach and Results-Low-density lipoprotein receptor knockout mice were fed a chow or a high-fat, high-cholesterol (HFHC) diet (42% fat, 0.2% cholesterol) for 4 weeks. For a further 8 weeks, the HFHC group was fed either HFHC or HFHC plus GW1516 (3 mg/kg per day). GW1516 significantly attenuated pre-established fasting hyperlipidemia, hyperglycemia, and hyperinsulinemia, as well as glucose and insulin intolerance. GW1516 intervention markedly reduced aortic sinus lesions and lesion macrophages, whereas smooth muscle alpha-actin was unchanged and collagen deposition enhanced. In aortae, GW1516 increased the expression of the PPAR delta-specific gene Adfp but not PPAR alpha- or gamma-specific genes. GW1516 intervention decreased the expression of aortic proinflammatory M1 cytokines, increased the expression of the anti-inflammatory M2 cytokine Arg1, and attenuated the iNos/Arg1 ratio. Enhanced mitogen-activated protein kinase signaling, known to induce inflammatory cytokine expression in vitro, was enhanced in aortae of HFHC-fed mice. Furthermore, the HFHC diet impaired aortic insulin signaling through Akt and forkhead box O1, which was associated with elevated endoplasmic reticulum stress markers CCAAT-enhancer-binding protein homologous protein and 78kDa glucose regulated protein. GW1516 intervention normalized mitogen-activated protein kinase activation, insulin signaling, and endoplasmic reticulum stress.Conclusions-Intervention with a PPAR delta agonist inhibits aortic inflammation and attenuates the progression of preestablished atherosclerosis.

PPAR Agonists Ameliorate Endothelial Cell Activation via Inhibition of Diacylglycerol–Protein Kinase C Signaling Pathway

Ppar Gamma Agonists Ameliorate Endothelial Cell Activation Via Inhibition of Diacylglycerol-Protein Kinase C Signaling Pathway - Role of Diacylglycerol Kinase

Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells

Pharmacological Activation of PPAR Gamma Ameliorates Vascular Endothelial Insulin Resistance Via a Non-Canonical PPAR Gamma-Dependent Nuclear Factor-Kappa B Trans-Repression Pathway.

PPARδ activation protects endothelial function in diabetic mice

PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment.

PPAR-gamma in the Cardiovascular System.

PPAR-γ in the Cardiovascular System

Trans‐repression of NFκB Pathway Mediated by PPARγ Improves Vascular Endothelium Insulin Resistance

Effects of PPARγ Agonists Against Vascular and Renal Dysfunction

PPARδ Agonist Prevents Endothelial Dysfunction Via Induction of Dihydrofolate Reductase Gene and Activation of Tetrahydrobiopterin Salvage Pathway

Peroxisome Proliferator–Activated Receptor Δ Agonist GW1516 Attenuates Diet-Induced Aortic Inflammation, Insulin Resistance, and Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice

Pleiotropic Actions of PPAR Gamma Activators Thiazolidinediones in Cardiovascular Diseases.

Adipocyte Signaling and Lipid Homeostasis: Sequelae of Insulin-Resistant Adipose Tissue Diabetic Cardiomyopathy: The Search for a Unifying Hypothesis Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals

Constitutive Activation of Peroxisome Proliferator-activated Receptor-γ Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells

The role of PPARs in atherosclerosis

Targeting PPARs for therapy of atherosclerosis: A review

The exogenous natural phospholipids, EPA-PC and EPA-PE, contributes to ameliorate lipid accumulation and inflammation via activation of PPARα/γ

PPAR gamma and PGC-1alpha activators protect against diabetic nephropathy by suppressing the inflammation and NF-kappaB activation

PPAR-gamma Ligands Inhibit the Expression of Inflammatory Cytokines and Attenuate Autoimmune Myocarditis.

Covalent Peroxisome Proliferator-Activated Receptor Gamma Adduction by Nitro-Fatty Acids: Selective Ligand Activity and Anti-Diabetic Signaling Actions.